PBH at a glance
Prestige Consumer Healthcare Inc. (PBH, SEC CIK 1295947) filed its latest 10-K annual report on May 14, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), Prestige Consumer Healthcare Inc. (PBH) reported revenue of $1.1 billion (down 4.3% from FY2025) and net income of $190.3 million. Diluted EPS was $3.91.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Prestige Consumer Healthcare Inc. (PBH) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Zerillo Jeffrey on May 11, 2026 of 351 shares at $52.28 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.1B
- −4.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $1.2B · +2 vs prior quarter
- Latest 8-K
- Aug 14, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $265.7M, up $16.2M or 6.5% YoY
- Gross margin 51.3% vs 56.2% YoY, pressured by Pillar5 optimization and inventory step-up amortization
- Best category Wellness, Sleep & Other revenue $14.3M, up 167.8% YoY across segments
- North American contribution margin 38.5% vs 43.0%; International contribution margin 36.7% vs 37.7%
- Cash $89.1M, up $25.3M; operating cash flow $70.8M vs $79.0M YoY
- Breathe Right acquisition drove $1,063.7M investing outflows and $1,018.5M financing inflows; supply shortages and inflation remained headwinds
Risk Factors
- Quarterly revenue volatility risk, with results potentially falling below analyst and investor expectations
- Market valuation risk, from weaker quarterly results adversely impacting outstanding securities
- No material new regulatory, legal, operational, competitive, or financial risks disclosed in provided text
AI summary of the PBH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeffrey Zerillo retiring as Senior Vice President, Operations effective August 14, 2026
- Departure includes all other positions Zerillo holds with Prestige Consumer Healthcare
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $265.7M, up 6.5%, with organic growth 3.2% exceeding expectations
- Adjusted EPS $0.98 versus $0.95, while GAAP EPS fell to $0.61 amid acquisition and facility-remediation costs
Item 7.01: Regulation FD Disclosure
- Investor Presentation disclosed under Regulation FD, with substantive content in Exhibits 99.1 and 99.2
- Presentation information supplemental to SEC filings and other public announcements
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q1 2026 results cover the quarter ended June 30, 2026
- Earnings press release issued August 6, 2026
Item 2.03: Creation of a Direct Financial Obligation
- Indenture dated July 15, 2026 establishes the terms governing Prestige’s 2026 notes
- Prestige Brands, Inc. and affiliated guarantors are obligated under the note structure
Item 1.01: Entry into a Material Definitive Agreement
- $400.0M senior notes issued at 6.250% interest, maturing July 15, 2034
- Annual interest expense of $25.0M, payable semiannually beginning January 15, 2027
AI summaries of PBH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PBH
Don't miss the next PBH filing
- Alerts as it files. A push when PBH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PBH, by share count.
- Ask anything. An AI agent that reads every PBH filing and answers with sources.
PBH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Clark Celeste A. | A | Aug 4, 2026 | 2,981 | - |
| BYOM JOHN E | A | Aug 4, 2026 | 2,981 | - |
| DArecca James | A | Aug 4, 2026 | 2,981 | - |
| Kelly John F. | A | Aug 4, 2026 | 2,981 | - |
| ZIER DAWN M. | A | Aug 4, 2026 | 2,981 | - |
| Zerillo Jeffrey | Sell | May 11, 2026 | 351 | $52.28 |
| Lombardi Ronald M. | F | May 7, 2026 | 2,543 | $54.59 |
| Sacco Christine | F | May 7, 2026 | 991 | $54.59 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.1B | $1.1B |
| Gross Profit | - | $634.5M | $595.6M |
| Operating Income | - | $336.8M | $309.4M |
| Net Income | - | $214.6M | $190.3M |
| Gross Margin | - | 55.8% | 54.7% |
| Op. Margin | - | 29.6% | 28.4% |
| Net Margin | - | 18.9% | 17.5% |
| Balance Sheet | |||
| Total Assets | $3.3B | $3.4B | $3.5B |
| Equity | - | $1.8B | $1.9B |
| ROE | - | 11.7% | 10.1% |
| Per Share | |||
| EPS | - | $4.29 | $3.91 |
| Cash Flow | |||
| Operating CF | - | $251.5M | $257.6M |
| CapEx | $9.6M | $8.2M | $11.2M |
Source: XBRL data in Prestige Consumer Healthcare Inc. (PBH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PBH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $1.21B |
| Q1 2026 | 33 | $1.50B |
| Q4 2025 | 30 | $1.60B |
| Q3 2025 | 32 | $1.71B |
| Q2 2025 | 31 | $2.24B |
| Q1 2025 | 29 | $1.64B |
| Q4 2024 | 26 | $1.27B |
| Q3 2024 | 22 | $686.1M |
- BlackRock+442.8K (+6%)
- Citadel Advisors LLC+380.7K (+208%)
- Prudential Financial+156.2K (+257%)
- State Street Corp+145.5K (+7%)
- Goldman Sachs Group+128.9K (+28%)
- WESTWOOD HOLDINGS GROUP INC−369.3K (-33%)
- Millennium Management−211.9K (-82%)
- T. Rowe Price Group−199.7K (-37%)
- Invesco Ltd−189.6K (-32%)
- Morgan Stanley−113.5K (-8%)
- Allstate+46.7K
- Bridgewater Associates LP+46.4K
- OLD NATIONAL BANCORP /IN/+4.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 238 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PBH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | May 14, 2026 | - | - | |
| 10-K | May 14, 2026 | Mar 31, 2026 | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PBH SEC filings: frequently asked questions
Which institutions hold PBH stock?
As of June 30, 2026, the largest Prestige Consumer Healthcare Inc. (PBH) holders among the 13F filers tracked by SignalX were BlackRock ($370.2 million), Vanguard Portfolio Management LLC ($133.6 million), Dimensional Fund Advisors ($125.8 million), Vanguard Capital Management LLC ($101.0 million), State Street Corp ($100.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PBH's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), Prestige Consumer Healthcare Inc. (PBH) reported revenue of $1.1 billion (down 4.3% from FY2025) and net income of $190.3 million. Diluted EPS was $3.91. The figures come from the XBRL data in the 10-K.
What did PBH report in its latest 8-K?
Prestige Consumer Healthcare Inc. (PBH) filed an 8-K on August 14, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Jeffrey Zerillo retiring as Senior Vice President, Operations effective August 14, 2026.
What are the latest PBH SEC filings?
Prestige Consumer Healthcare Inc. (PBH) filed its latest 10-K annual report on May 14, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on August 5, 2026.
What is PBH's SEC CIK number?
Prestige Consumer Healthcare Inc. (PBH)'s SEC Central Index Key (CIK) is 1295947. EDGAR lists every PBH filing under that number.
Ask anything about PBH
The research agent reads PBH's filings, financials, insider trades and 13F holders, then answers with sources.